Inflammatory aspects of glucose in hyperlipidemia and diabetes

Inflammatory aspects of glucose in hyperlipidemia and diabetes - INFORM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31196

Enrollment

Registered

2007-09-04

Start date

2007-10-25

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Hyperlipidemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: ·Provide written informed consent ·Aged 45-65 years ·BMI

Exclusion criteria

Exclusion criteria: ·Emotionally and intellectually not capable to decide about participation in the study and the consequences of participation. Subjects who are not able to understand the patient information ·Diabetes mellitus treated with oral antidiabetic medicine .Type 1 diabetes mellitus ·peripheral artery and/or coronary disease .Untreated hypertension ·Alcohol use > 2 units/day ·Aberrations in kidney, liver and thyroid function ·Use of any experimental medication within 6 months of the study ·The use of immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
In this study, inflammatory aspects (leukocyte activation and complement system) in different groups of subjects will be investigated during an OGTT.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results